PSG8 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with PSG8 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with PSG8 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with PSG8 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PSG8 Up.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000159352 - proteasome 26S subunit ubiquitin receptor, non-ATPase 4

Gene

ENSG00000135940 - cytochrome c oxidase subunit 5B

Gene

ENSG00000178741 - cytochrome c oxidase subunit 5A

Gene

ENSG00000138398 - peptidylprolyl isomerase G

Gene

ENSG00000037241 - ribosomal protein L26 like 1

Gene

ENSG00000243646 - interleukin 10 receptor subunit beta

Gene

ENSG00000138459 - solute carrier family 35 member A5

Gene

ENSG00000154518 - ATP synthase membrane subunit c locus 3

  • Gene

    ENSG00000159352 - proteasome 26S subunit ubiquitin receptor, non-ATPase 4


  • Gene

    ENSG00000135940 - cytochrome c oxidase subunit 5B


  • Gene

    ENSG00000178741 - cytochrome c oxidase subunit 5A


  • Gene

    ENSG00000138398 - peptidylprolyl isomerase G


  • Gene

    ENSG00000037241 - ribosomal protein L26 like 1


  • Gene

    ENSG00000243646 - interleukin 10 receptor subunit beta


  • Gene

    ENSG00000138459 - solute carrier family 35 member A5


  • Gene

    ENSG00000154518 - ATP synthase membrane subunit c locus 3

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.